Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
Oncotarget
.
2018 Jul 31;9(59):31559.
doi: 10.18632/oncotarget.25943.
Authors
Po-Hao Feng
1
2
,
Chih-Teng Yu
3
,
Kuan-Yuan Chen
1
4
,
Ching-Shan Luo
1
,
Shen Ming Wu
1
,
Chien-Ying Liu
3
,
Lu Wei Kuo
1
,
Yao-Fei Chan
3
,
Tzu-Tao Chen
1
,
Chih-Cheng Chang
1
,
Chun-Nin Lee
1
,
Hsiao-Chi Chuang
5
,
Chiou-Feng Lin
6
,
Chia-Li Han
7
,
Wei-Hwa Lee
8
,
Kang-Yun Lee
1
2
Affiliations
1
Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
2
Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
3
Division of Pulmonary Medicine, Department of Internal Medicine, Chang Gung Medical Foundation Linko Branch, Taoyuan, Taiwan.
4
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
5
School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan.
6
Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
7
Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
8
Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
PMID:
30140390
PMCID:
PMC6101133
DOI:
10.18632/oncotarget.25943
Abstract
[This corrects the article DOI: 10.18632/oncotarget.24146.].
Publication types
Published Erratum